Overview

Gender

male

Mark Iwicki has more than 23 years of experience as a pharmaceutical industry leader managing all stages of drug development in multiple therapeutic areas.

He has extensive experience managing high-performance teams and has been instrumental in the success of a number of drugs, including Prilosec®, Diovan®, Zelnorm®, Lunesta®, and Latuda®.

Prior to joining Blend, Mr. Iwicki was CEO of Sunovion Pharmaceuticals, where he provided leadership to the successful launch of Sunovion, which was created after the $2.6 billion acquisition of Sepracor by Dainippon Sumitomo Pharmaceuticals. At Sepracor, Mr. Iwicki served as Chief Commercial Officer for the company’s six marketed products with over $1.2 billion in annual sales.

Prior to joining Sepracor in 2007, he was the Senior Vice President and head of the $4 billion cardiovascular business unit at Novartis Pharmaceuticals, and before that held management positions at Astra Merck and Merck.